Page 90 - Cardiac Nursing

p
6 A
2-0
p
ta
ta
p
1
1
5:3
6 A
2-0
04
04
r
0/2
0/2
009
6/3
0
0
6/3
q
q
r
xd
009
0
xd
q
68.
02_
p
e 6
e 6
68.
g
LWB
K34
LWBK340-c02_ p pp042-068.qxd 06/30/2009 15:33 Page 66 Aptara a a
LWB
0-c
02_
K34
0-c
Pa
Pa
g
g
3
5:3
Pa
3
66 PA R T I / Anatomy and Physiology
70. Brunner, F., Bras-Silva, C., Cerdeira, A. S., et al. (2006). Cardiovascular 92. Friedewald, V. E., Jr., Bennett, J. S., Packer, M., et al. (2008). The edi-
endothelins: Essential regulators of cardiovascular homeostasis. Pharma- tor’s roundtable: Nonsteroidal antiinflammatory drugs and cardiovascu-
cology Therapeutics, 111, 508–531. lar risk. American Journal of Cardiology, 102, 1046–1055.
71. Masson, S., Latini, R., Anand, I. S., et al. (2006). The prognostic value 93. Harrison, D., Griendling, K. K., Landmesser, U., et al. (2003). Role of
of big endothelin-1 in more than 2,300 patients with heart failure oxidative stress in atherosclerosis. American Journal of Cardiology, 91,
enrolled in the Valsartan Heart Failure Trial (Val-HeFT). Journal of 7A–11A.
Cardiac Failure, 12, 375–380. 94. Forstermann, U. (2008). Oxidative stress in vascular disease: Causes,
72. Feldstein, C., & Romero, C. (2007). Role of endothelins in hyperten- defense mechanisms and potential therapies. Nature Clinical Practice, 5,
4
4
sion. American Journal of Therapeutics, 14, 147–153. 338–349.
73. O’Connor, C. M., Gattis, W. A., Adams, K. F., Jr., et al. (2003). 95. Bonomini, F., Tengattini, S., Fabiano, A., et al. (2008). Atherosclerosis
Tezosentan in patients with acute heart failure and acute coronary syn- and oxidative stress. Histology and Histopathology, 23, 381–390.
dromes: Results of the Randomized Intravenous TeZosentan Study 96. Hornig, B., Landmesser, U., Kohler, C., et al. (2001). Comparative ef-
(RITZ-4). Journal of the American College of Cardiology, 41, 1452–1457. fect of ace inhibition and angiotensin II type 1 receptor antagonism on
74. Anand, I., McMurray, J., Cohn, J. N., et al. (2004). Long-term effects bioavailability of nitric oxide in patients with coronary artery disease:
of darusentan on left-ventricular remodelling and clinical outcomes in Role of superoxide dismutase. Circulation, 103, 799–805.
the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): 97. McQueen, M. J., Lonn, E., Gerstein, H. C., et al. (2005). The HOPE
Randomised, double-blind, placebo-controlled trial. Lancet, 364, (Heart Outcomes Prevention Evaluation) Study and its consequences.
347–354. Scandinavian Journal of Clinical Laboratory Investigations Supplement,
75. Sica, D. A. (2008). Endothelin receptor antagonism: What does the fu- 240, 143–156.
ture hold? Hypertension, 52, 460–461. 98. Landmesser, U., Bahlmann, F., Mueller, M., et al. (2005). Simvastatin
76. Van Guilder, G. P., Westby, C. M., Greiner, J. J., et al. (2007). En- versus ezetimibe: Pleiotropic and lipid-lowering effects on endothelial
dothelin-1 vasoconstrictor tone increases with age in healthy men but function in humans. Circulation, 111, 2356–2363.
can be reduced by regular aerobic exercise. Hypertension, 50, 403–409. 99. Lonn, E., Bosch, J., Yusuf, S., et al. (2005). Effects of long-term vitamin E
77. Ivey, M. E., Osman, N., & Little, P. J. (2008). Endothelin-1 signalling supplementation on cardiovascular events and cancer: A randomized con-
in vascular smooth muscle: Pathways controlling cellular functions asso- trolled trial. Journal of the American Medical Association, 293, 1338–1347.
ciated with atherosclerosis. Atherosclerosis, 199, 237–247. 100. Vivekananthan, D., Penn, M., Sapp, S., et al. (2003). Use of antioxidant
78. Rubin, L. J., Badesch, D. B., Barst, R. J., et al. (2002). Bosentan ther- vitamins for the prevention of cardiovascular disease: Meta-analysis of
apy for pulmonary arterial hypertension. New England Journal of Medi- randomised trials. Lancet, 361, 2017–2023.
6
cine, 346, 896–903. 101. Bjelakovic, G., Nikolova, D., Simonetti, R. G., et al. (2008). Systematic
6
79. Denton, C. P., Pope, J. E., Peter, H. H., et al. (2008). Long-term effects review and meta-analysis: Primary and secondary prevention of gas-
of bosentan on quality of life, survival, safety and tolerability in pul- trointestinal cancers with antioxidant supplements. Alimentary Pharma-
monary arterial hypertension related to connective tissue diseases. Annals cology and Therapies, 28(6), 689–703.
7
7
of Rheumatic Diseases, 67, 1222–1228. 102. Marshall, J. M. (2002). Roles of adenosine in skeletal muscle during sys-
80. Le Brocq, M., Leslie, S. J., Milliken, P., et al. (2008). Endothelial dys- temic hypoxia. Clinical and Experimental Pharmacology and Physiology,
function: From molecular mechanisms to measurement, clinical impli- 29, 843–849.
cations, and therapeutic opportunities. Antioxidants and Redox Signals, 103.Ralevic, V. (2002). Hypoxic vasodilatation: Is an adenosine-
10, 1631–1674. prostaglandins-NO signalling cascade involved? Journal of Physiology
4
4
81. Antithrombotic Trialists’ Collaboration (2002). Collaborative meta- (London), 544, 2.
analysis of randomised trials of antiplatelet therapy for prevention of 104. Ray, C. J., Abbas, M. R., Coney, A. M., et al. (2002). Interactions of
4
4
death, myocardial infarction, and stroke in high risk patients. BMJ, 324, adenosine, prostaglandins and nitric oxide in hypoxia-induced vasodi-
4
4
71–86. latation: In vivo and in vitro studies. Journal of Physiology (London), 544,
82. Ridker, P. M., Cook, N. R., Lee, I. M., et al. (2005). A randomized trial 195–209.
of low-dose aspirin in the primary prevention of cardiovascular disease 105. Koller, A., & Bagi, Z. (2002). On the role of mechanosensitive mecha-
in women. New England Journal of Medicine, 352, 1293–1304. nisms eliciting reactive hyperemia. American Journal of Physiology, 283,
83. Eikelboom, J. W., Hankey, G. J., Thom, J., et al. (2008). Incomplete in- H2250–H2259.
hibition of thromboxane biosynthesis by acetylsalicylic acid: Determi- 106. Flavahan, N., Cooke, J., Shepherd, J., et al. (1987). Human postjunc-
nants and effect on cardiovascular risk. Circulation, 118, 1705–1712. tional alpha-1 and alpha-2 adrenoreceptors: Differential distribution in
84. Bombardier, C., Laine, L., Reicin, A., et al. (2000). Comparison of up- arteries and limbs. Journal of Pharmacology and Experimental Therapeu-
per gastrointestinal toxicity of rofecoxib and naproxen in patients with tics, 241, 361–365.
rheumatoid arthritis. VIGOR Study Group. New England Journal of 107.Civantos Calzada, B., & Aleixandre de Artinano, A. (2001). Alpha-
4
Medicine, 343, 1520–1528. adrenoceptor subtypes. Pharmacology Research, 44, 195–208.
4
85. Bresalier, R. S., Sandler, R. S., Quan, H., et al. (2005). Cardiovascular 108. Kable, J., Murrin, L., & Bylund, D. B. (2000). In vivo gene modifica-
events associated with rofecoxib in a colorectal adenoma chemopreven- tion elucidates subtype-specific functions of alpha (2)-adrenergic recep-
tion trial. New England Journal of Medicine, 352, 1092–1102. tors. Journal of Pharmacology and Experimental Therapeutics, 293, 1–7.
86. U.S. Food and Drug Administration. (2005). Alert for healthcare profes- 109. Kanagy, N. L. (2005). Alpha(2)-adrenergic receptor signalling in hyper-
sionals: Non-selective non-steroidal antiinflammatory drugs (NASIDs). tension. Clinical Science (London), 109, 431–437.
Silver Spring, MD: U.S. Department of Health and Human Services. 110. Leech, C. J., & Faber, J. E. (1996) Different alpha-adrenoceptor sub-
87. McGettigan, P., & Henry, D. (2006). Cardiovascular risk and inhibition types mediate constriction of arterioles and venules. American Journal of
of cyclooxygenase: A systematic review of the observational studies of se- Physiology, 270, H710–H722.
lective and nonselective inhibitors of cyclooxygenase 2. Journal of the 111. Feigl, E. O. (1998). Neural control of coronary blood flow. Journal of
American Medical Association, 296, 1633–1644. Vascular Research, 35, 85–92.
6
6
88. Warner, J. J., Weideman, R. A., Kelly, K. C., et al. (2008). The risk of 112. Barbato, E., Piscione, F., Bartunek, J., et al. (2005). Role of beta2 adren-
acute myocardial infarction with etodolac is not increased compared to ergic receptors in human atherosclerotic coronary arteries. Circulation,
naproxen: A historical cohort analysis of a generic COX-2 selective in- 111, 288–294.
hibitor. Journal of Cardiovascular Pharmacology and Therapies, 13(4), 113. Gauthier, C., Seze-Goismier, C., & Rozec, B. (2007). Beta 3-adrenoceptors
252–260. in the cardiovascular system. Clinical Hemorheology and Microcirculation,
89. Roumie, C. L., Mitchel, E. F., Jr., Kaltenbach, L., et al. (2008). 37, 193–204.
7
7
Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for 114. Gauthier, C., Leblais, V., Kobzik, L., et al. (1998). The negative in-
stroke. Stroke, 39, 2037–2045. otropic effect of B3-Adrenoreceptor stimulation is mediated by activa-
90. Grosser, T., Fries, S., & FitzGerald, G. A. (2006). Biological basis for the tion of nitric oxide synthase pathway in human ventricle. Journal of
cardiovascular consequences of COX-2 inhibition: Therapeutic chal- Clinical Investigations, 102, 1377–1384.
6
6
lenges and opportunities. Journal of Clinical Investigations, 116, 4–15. 115. Moniotte, S., Kobzik, L., Feron, O., et al. (2001). Upregulation of
91. Funk, C. D., & FitzGerald, G. A. (2007). COX-2 inhibitors and car- beta(3)-adrenoreceptors and altered contractile response to inotropic
diovascular risk. Journal of Cardiovascular Pharmacology, 50, 470–479. amines in human failing myocardium. Circulation, 103, 1649–1655.